Goldman Sachs Maintains Buy on Boston Scientific, Lowers Price Target to $93

Benzinga Newsdesk www.benzinga.com Negative 65.1%

Neg 65.1% Neu 0% Pos 0%

Goldman Sachs analyst David Roman maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $98 to $93.